Etiology and Pathogenesis in Primary Sclerosing Cholangitis

References

• Warren K W, Athanassiades S, Monge J I. Primary sclerosing cholangitis. A study of forty-two cases. Am J Surg 1966; 111: 23–38
   PubMed Web of Science ®Google Scholar
• Chapman R WG, Marborgh B A, Rhodes J M, Summerfield J A, Dick R, Scheuer P J, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870–7
   PubMed Web of Science ®Google Scholar
• Wiesner R H, LaRusso N F. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200–6
   PubMed Web of Science ®Google Scholar
• Ayoola E A, Vennes J A, Silvis S E, Rohrmann C A, Ansel H J. Endoscopic retrograde intrahepatic cholangiography in liver diseases. Gastrointest Endosc 1976; 22: 156–9
   PubMed Web of Science ®Google Scholar
• Holubitsky I B, McKenzie A D. Primary sclerosing cholangitis of the extrahepatic bile ducts. Can J Surg 1964; 7: 277–83
   PubMedGoogle Scholar
• MacCarty R L, LaRusso N F, Wiesner R H, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983; 149: 39–44
   PubMed Web of Science ®Google Scholar
• Wiesner R H, Grambsch P M, Dickson E R, Ludwig J, MacCarty R L, Hunter E B, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepa-tology 1989; 10: 430–6
   PubMed Web of Science ®Google Scholar
• Farrant J M, Hayllar K M, Wilkinson M L, Karani J, Portmann B C, Westaby D, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100: 1710–7
   PubMed Web of Science ®Google Scholar
• Schrumpf E, Fausa O, Kolmannskog F, Elgjo K, Ritland S, Gjone E. Sclerosing cholangitis in ulcerative colitis. A follow-up study. Scand J Gastroenterol 1982; 17: 33–9
   PubMed Web of Science ®Google Scholar
• Ludwig J, Barham S S, LaRusso N F, Elveback L R, Wiesner R H, McCall J T. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1: 632–40
   PubMedGoogle Scholar
• Barbatis C, Grases P, Shepherd H A, Chapman R W, Trowell J, Jewell D PJ, et al. Histological features of sclerosing cholangitis in patients with ulcerative colitis. J Clin Pathol 1985; 38: 778–83
   PubMed Web of Science ®Google Scholar
• Marsh J W, Iwatsuki S, Makowka L, Esquivel C O, Gordon R D, Todo S, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg 1988; 207: 21–5
   PubMed Web of Science ®Google Scholar
• Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987; 22: 655–64
   PubMed Web of Science ®Google Scholar
• Quigley E MM, Beaver S J, Wiesner R H, LaRusso N F. Familial occurrence of liver disease and inflammatory bowel disease in primary sclerosing cholangitis. Gastroenterology 1987; 92: 1585
   Google Scholar
• Schrumpf E, Fausa O, Elgjo K, Kolmannskog F. Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988; 8: 201–9
   PubMed Web of Science ®Google Scholar
• El-Shabrawi M, Wilkinson M L, Portmann B, Mieli-Vergani G, Chong S KF, Williams R, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987; 92: 1226–35
   PubMedGoogle Scholar
• Sinha A A, Lopez M T, McDevitt H O. Autoimmune diseases: the failure of self-tolerance. Science 1990; 248: 1380–8
   PubMed Web of Science ®Google Scholar
• Bodmer J G, Marsh S G, Albert E D, Bodmer W F, Dupont B, Erlich H A, et al. Nomenclature for factors of the HLA system, 1991. Tissue Antigens 1992; 39: 161–73
   PubMedGoogle Scholar
• Campbell R D, Trowsdale J. Map of the human MHC. Immunol Today 1993; 14: 349–52
   PubMedGoogle Scholar
• Schrumpf E, Fausa O, Førre Ø, Dobloug J H, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982; 17: 187–91
   PubMed Web of Science ®Google Scholar
• Chapman R W, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983; 24: 38–41
   PubMed Web of Science ®Google Scholar
• Shepherd H A, Selby W S, Chapman R WG, Nolan D, Barbatis C, McGee J O'D, et al. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983; 208: 503–13
   Google Scholar
• Donaldson P T, Farrant J M, Wilkinson M L, Hayllar K, Portmann B C, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991; 13: 129–33
   PubMed Web of Science ®Google Scholar
• Prochazka E J, Terasaki P I, Park M S, Goldstein L I, Busuttil R W. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990; 322: 1842–4
   PubMed Web of Science ®Google Scholar
• Grunnet N, Rasmussen H H, Tage-Jensen U, Rasmussen Nørby S. Association of primary sclerosing cholangitis with HLA-DRw52a?. Tissue Antigens 1991; 38: 133–6
   PubMedGoogle Scholar
• Farrant J M, Doherty D G, Donaldson P T, Vaughan R W, Hayllar K M, Welsh K I, et al. Amino acid substitutions at position 38 of the DRβ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992; 16: 390–5
   PubMedGoogle Scholar
• Mehal W Z, Lo Y-M D, Wordsworth B P, Neuberger J M, Hubscher S C, Fleming K A, et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1994; 106: 160–7
   PubMedGoogle Scholar
• Zetterquist H, Broomé U, Einarsson K, Olerup O. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992; 33: 942–6
   PubMedGoogle Scholar
• Amar A, Brautbar C, Goldin E, Sherman L, Barmeir S, Shouval D, et al. Serological and molecular analysis of HLA in Israeli primary sclerosing cholangitis patients. Eur J Immunogen 1992; 19: 295–302
   PubMedGoogle Scholar
• Vierling J M. Immune disorders of the liver and bile duct. Gastroenterol Clin N Am 1992; 21: 427–49
   PubMedGoogle Scholar
• Quigley E MM, LaRusso N F, Ludwig J, MacSween R NM, Birnie G G, Watkinson G. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983; 85: 1160–5
   PubMed Web of Science ®Google Scholar
• Jorge A D, Esley C, Ahumada J. Family incidence of primary sclerosing cholangitis associated with immunologic diseases. Endoscopy 1987; 19: 114–7
   PubMedGoogle Scholar
• Silber G H, Finegold M J, Wagner M L, Klish W J. Sclerosing cholangitis and ulcerative colitis in a mother and her son. J Pediatr Gastroenterol Nutr 1987; 6: 147–52
   PubMedGoogle Scholar
• McFarlane I G, Wojcicka B M, Tsantoulas D C, Portmann B C, Eddleston A LWF, Williams R. Leukocyte migration inhibition in response to biliary antigens in primary biliary cirrhosis. sclerosing cholangitis, and other chronic liver diseases. Gastroenterology 1979; 76: 1333–40
   PubMed Web of Science ®Google Scholar
• Whiteside T L, Lasky S, Si L, Van Thiel D H. Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology 1985; 5: 468–74
   PubMed Web of Science ®Google Scholar
• Lindor K D, Wiesner R H, Katzmann J A, LaRusso N F, Beaver S I. Lymphocyte subsets in primary sclerosing cholangitis. Dig Dis Sci 1987; 32: 720–5
   PubMedGoogle Scholar
• Snook J A, Chapman R W, Sachdev G K, Heryet A, Kelly P MA, Fleming K A, et al. Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J Hepatol 1989; 9: 36–41
   PubMedGoogle Scholar
• Mieli-Vergani G, Lobo-Yeo A, McFarlane B M, McFarlane I G, Mowat A P, Vergani D. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood. Hepatology 1989; 9: 198–203
   PubMed Web of Science ®Google Scholar
• Broomé U, Hultcrantz R, Scheynius A. Lack of concomitant expression of ICAM-1 and HLA-DR on bile duct cells from patients with primarv sclerosing cholangitis and primary biliary cirrhosis. Scand J Gastroenterol 1993; 28: 126–30
   PubMed Web of Science ®Google Scholar
• Nagata M, Yokono K, Hayakawa M, Kawase Y, Hatamori N, Ogawa W, et al. Destruction of pancreatic islet cells by cytotoxic T lymphocytes in nonobese diabetic mice. J Immunol 1989; 143: 1155–62
   PubMedGoogle Scholar
• Broomé U, Scheynius A, Hultcrantz R. Induced expression of heat shock protein on biliary epithelium in patients with primarv sclerosing cholangitis and primarv biliary cirrhosis. Hepatology 1993; 18: 298–303
   PubMedGoogle Scholar
• Jeffrey G P, Reed W D, Carrello S, Shilkin K B. Histological and immunohistochemical study of the gall bladder lesion in primarv sclerosing cholangitis. Gut 1991; 32: 424–9
   PubMedGoogle Scholar
• Lindor K D, Wiesner R H, LaRusso N F, Homburger H A. Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis. Hepatology 1987; 7: 884–8
   PubMed Web of Science ®Google Scholar
• Kilby A E, Krawitt E L, Albertini R J, Chastenay B F, John A. Suppressor T-cell deficiency in primary sclerosing cholangitis. Case and family study. Dig Dis Sci 1991; 36: 1213–6
   PubMedGoogle Scholar
• Magrin S, Nouri-Aria K T, Donaldson P T, Wilkinson M L, Portmann B C, Williams R, et al. The relationship between HLA-DR3 and T-cell regulation of immunoglobulin production in primary sclerosing cholangitis. Clin Immunol Immunopathol 1989; 50: 205–12
   PubMedGoogle Scholar
• Nouri-Aria K T, Donaldson P T, Hegartv J E, Eddleston A LWF, Williams R. HLA A1-B8-DR3 arid suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. J Hepatol 1985; 1: 235–41
   PubMed Web of Science ®Google Scholar
• Ohashi P S, Oehen S, Buerki K, Pircher H, Ohashi C T, Odermatt B, et al. Ablation of tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991; 65: 305–17
   PubMed Web of Science ®Google Scholar
• Aria Nouri KT, Lombard M, Williams R. High serum levels of CD8 antigen in primary biliary cirrhosis: a possible cause of suppressor cell dysfunction?. Clin Exp Immunol 1991; 86: 140–4
   PubMedGoogle Scholar
• Boberg K M, Aukrust P, Müller F, Frøland S, Schrumpf E. Elevated levels of soluble CD8 antigen and neopterin in primary sclerosing cholangitis. J Hepatol 1993; 18(Suppl 1)S97, (T-50)
   Google Scholar
• Botazzo G F, Pujol-Borrell R, Hanafusa T. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; 2: 1115–9
   PubMed Web of Science ®Google Scholar
• Van den Oord J J, Sciot R, Desmct V J. Expression of MHC products by normal and abnormal bile duct epithelium. J Hepatol 1986; 3: 310–7
   PubMed Web of Science ®Google Scholar
• Ballardini G, Mirakian R, Bianchi F B, Pisi E, Doniach D, Botazzo G F. Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 1984; 2: 1009–13
   PubMed Web of Science ®Google Scholar
• Spengler U, Pape G R, Hoffmann R M, Johnson J P, Eisenburg J, Paumgartner G, et al. Differential expression of MHC class II subregion products on bile duct epithelial cells and hepatocytes in patients with primary biliary cirrhosis. Hepatology 1988; 8: 459–62
   PubMed Web of Science ®Google Scholar
• Chapman R W, Kelly P MA, Heryet A, Jewell D P, Fleming K A. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 1988; 29: 422–7
   PubMed Web of Science ®Google Scholar
• Broomé U, Glaumann H, Hultcrantz R, Forsum U. Distribution of HLA-DR, HLA-DP, HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scand J Gastroenterol 1990; 25: 54–8
   PubMed Web of Science ®Google Scholar
• Lobo-Yeo A, Senaldi G, Portmann B, Mowat A P, Mieli-Vergani G, Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a studv in children with liver disease. Hepatology 1990; 12: 224–32
   PubMed Web of Science ®Google Scholar
• Himeno H, Saibara T, Onishi S, Yamamoto Y, Enzan H. Administration of interleukin-2 induces major histocompatibility complex class II expression on the biliary epithelial cells, possibly through endogenous interferon-γ production. Hepatology 1992; 16: 409–17
   PubMedGoogle Scholar
• Springer T A. Adhesion receptors of the immune system. Nature 1990; 346: 425–34
   PubMed Web of Science ®Google Scholar
• Volpes R, van den Oord J J, Desmet V J. Can hepatocytes serve as ‘activated’ immunomodulating cells in the immune response?. J Hepatol 1992; 16: 228–40
   PubMedGoogle Scholar
• Patarroyo M, Makgoba M W. Leukocyte adhesion to cells in immune and inflammatory responses. Lancet 1989; 2: 1139–42
   PubMed Web of Science ®Google Scholar
• Adams D H, Hubscher S G, Shaw J, Johnson G D, Babbs C, Rothlein R, et al. Increased expression of intercellular adhesion molecule 1 on bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1991; 14: 426–31
   PubMed Web of Science ®Google Scholar
• Ayres R CS, Neuberger J M, Shaw J, Adams D H. In vitro induction of ICAM-1 and MHC antigens on human biliary epithelial cells by proinflammatory cytokines. Hepatology 1991; 14: 97A
   Google Scholar
• Adams D H, Mainolfi E, Burra P, Neuberger J M, Ayres R, Elias E, et al. Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases. Hepatology 1992; 16: 810–4
   PubMed Web of Science ®Google Scholar
• Zohrens G, Armbrust T, Pirzer U, Meyer zum Büschenfelde K-H, Ramadori G. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: relationship to disease activity and cirrhosis. Hepatology 1993; 18: 798–802
   PubMed Web of Science ®Google Scholar
• Schrumpf E, Elgjo K, Fausa O, Gjone E, Kolmannskog F, Ritland S. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15: 689–97
   PubMed Web of Science ®Google Scholar
• Boberg K M, Schrumpf E, Fausa O, Elgjo K, Kolmannskog F, Haaland T, et al. Hepatobiliary disease in ulcerative colitis. An analysis of 18 patients with major hepatic lesions other than classical primary sclerosing cholangitis. Scand J Gastroenterol
   Google Scholar
• Zauli D, Schrumpf E, Crespi C, Cassani F, Fausa O, Aadland E. An autoantibody profile in primary sclerosing cholangitis. J Hepatol 1987; 5: 14–8
   PubMedGoogle Scholar
• Kirby D F, Blei A T, Rosen S T, Vogelzang R L, Neiman H L. Primary sclerosing cholangitis in the presence of a lupus anticoagulant. Am J Med 1986; 81: 1077–80
   PubMedGoogle Scholar
• Mistilis S P, Blackburn C RB. Active chronic hepatitis. Am J Med 1970; 48: 484–95
   PubMed Web of Science ®Google Scholar
• Bodenheimer H C, LaRusso N F, Thayer W R, Jr., Charland C, Staples P J, Ludwig J. Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology 1983; 3: 150–4
   PubMed Web of Science ®Google Scholar
• Senaldi G, Donaldson P T, Magrin S, Farrant J M, Alexander G JM, Vergani D, et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 1989; 97: 1430–4
   PubMed Web of Science ®Google Scholar
• Minuk G Y, Angus M, Brickman C M, Lawley T J, Frank M M, Hoofnagle J H, et al. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 1985; 88: 166–70
   PubMedGoogle Scholar
• Alberti-Flor J J, de Medina M, Jeffers L, Schultz D R, Schiff E R. Elevated levels of immunoglobulins and immune complexes in the bile of patients with primary sclerosing cholangitis. Am J Gastroenterol 1986; 81: 325–8
   PubMedGoogle Scholar
• Brinch L, Teisberg P, Schrumpf E, Akesson I. The in vivo metabolism of C3 in hepatobiliary disease associated with ulcerative colitis. Scand J Gastroenterol 1982; 17: 523–7
   PubMed Web of Science ®Google Scholar
• Halstensen T S, Mollnes T E, Garred P, Fausa O, Brandtzaeg P. Epithelial deposition of immunoglobulin Gl and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 1990; 98: 1264–71
   PubMed Web of Science ®Google Scholar
• Chapman R W, Cottone M, Selby W S, Shepherd H A, Sherlock S, Jewell D P. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 1986; 27: 86–91
   PubMed Web of Science ®Google Scholar
• Snook J A, Chapman R W, Fleming K, Jewell D P. Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1989; 76: 30–3
   PubMed Web of Science ®Google Scholar
• Takahashi F, Das K M. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest 1985; 76: 311–8
   PubMed Web of Science ®Google Scholar
• Halstensen T S, Das K M, Brandtzaeg P. Epithelial deposits of immunoglobulin Gl and activated complement colocalize with the M, 40 kD putative autoantigen in ulcerative colitis. Gut 1993; 34: 650–7
   PubMed Web of Science ®Google Scholar
• Das K M, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98: 464–9
   PubMed Web of Science ®Google Scholar
• Mandal A, Dasgupta A, Jeffers L, Squillante L, Hyder S, Reddy R, et al. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology 1994; 106: 185–92
   PubMedGoogle Scholar
• Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86: 202–10
   PubMed Web of Science ®Google Scholar
• Duerr R H, Targan S R, Landers C J, LaRusso N F, Lindsay K L, Wiesner R H, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 1385–91
   PubMed Web of Science ®Google Scholar
• Klein R, Eisenburg J, Weber P, Seibold F, Berg P A. Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology 1991; 14: 1147–52
   PubMedGoogle Scholar
• Seibold F, Weber P, Klein R, Berg P A, Wiedmann K H. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992; 33: 657–62
   PubMed Web of Science ®Google Scholar
• Lo S K, Fleming K A, Chapman R W. Prevalence of anti-neu-trophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut 1992; 33: 1370–5
   PubMedGoogle Scholar
• Zauli D, Baffoni L, Cassani F, Fusconi M, Lenzi M, Ballardini G, et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis, ulcerative colitis, and autoimmune diseases. Gastroenterology 1992; 102: 1088–9
   PubMedGoogle Scholar
• Mulder A HL, Horst G, Haagsma E B, Limburg P C, Kleibeuker J H, Kallenberg C GM. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411–7
   PubMed Web of Science ®Google Scholar
• Lo S K, Chapman R W, Fleming K A. Tissue distribution of autoantigen specific for primary sclerosing cholangitis. J Clin Pathol 1993; 46: 246–9
   PubMedGoogle Scholar
• Vidrich A, Landers C, Sandborn B, Wiesner R H, Lindor K D, Targan S R. IgG subclass distinguishes between PSC and UC ANCA. Gastroenterology 1993; 104: A1015
   Google Scholar
• Peters M, Vierling J, Gershwin M E, Milich D, Chisari F V, Hoofnagle J H. Immunology and the liver. Hepatology 1991; 13: 977–94
   PubMed Web of Science ®Google Scholar
• Kovacs E J. Fibrogeniccytokines:theroleofimmunemediators in the development of scar tissue. Immunol Today 1991; 12: 17–23
   PubMedGoogle Scholar
• Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver disease. Effects of interferon alf a therapy. N Engl J Med 1991; 324: 933–40
   PubMed Web of Science ®Google Scholar
• Miller L C, Kaplan M M. Serum interleukin-2 and tumor necrosis factor-α in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am J Gastroenterol 1992; 87: 465–70
   PubMedGoogle Scholar
• Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264–74
   PubMed Web of Science ®Google Scholar
• Jones A, Selby P J, Viner C, Hobbs S, Gore M E, McElwain T J. Tumour necrosis factor, cholestatic jaundice, and chronic liver disease. Gut 1990; 31: 938–9
   PubMedGoogle Scholar
• Broome U, Eriksson L S, Sundin U, Sundquist K-G. Decreased in vitro production of tumor necrosis factor in primary biliary cirrhosis patients. Scand J Gastroenterol 1992; 27: 124–8
   PubMed Web of Science ®Google Scholar
• Müller M M, Curtius H-C, Herold M, Huber C H. Neopterin in clinical practice. Clin Chim Acta 1991; 201: 1–16
   PubMed Web of Science ®Google Scholar
• Boden R W, Rankin J G, Goulston S JM, Morrow W. The liver in ulcerative colitis. The significance of raised serum-alkaline-phosphatase levels. Lancet 1959; 2: 245–8
   PubMedGoogle Scholar
• Brooke B N, Dykes P W, Walker F C. A study of liver disorder in ulcerative colitis. Postgrad Med J 1961; 37: 245–51
   PubMed Web of Science ®Google Scholar
• Triger D R. Endotoxemia in liver disease—time for reappraisal?. J Hepatol 1991; 12: 136–8
   PubMed Web of Science ®Google Scholar
• Hobson C H, Butt T J, Ferry D M, Hunter J, Chadwick V S, Broom M F. Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis. Gastroenterology 1988; 94: 1006–13
   PubMed Web of Science ®Google Scholar
• Lichtman S N, Sartor R B, Keku J, Schwab J H. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98: 414–23
   PubMed Web of Science ®Google Scholar
• Vinnik I E, Kern F, Jr, Struthers J E, Jr, Hill R B, Guzak S. Experimental chronic portal vein bacteremia. Proc Soc Exp Biol Med 1964; 115: 311–4
   PubMedGoogle Scholar
• Kono K, Ohnishi K, Omata M, Saito M, Nakayama T, Hatano H, et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology 1988; 94: 787–96
   PubMed Web of Science ®Google Scholar
• Fox E S, Broitman S A, Thomas P. Biology of disease. Bacterial endotoxins and the liver. Lab Invest 1990; 63: 733–41
   PubMed Web of Science ®Google Scholar
• Nolan J P. Intestinal endotoxins as mediators of hepatic injury—an idea whose time has come again. Hepatology 1989; 10: 887–91
   PubMed Web of Science ®Google Scholar
• Cangemi J R, Wiesner R H, Beaver S J, Ludwig J, MacCarty R L, Dozois R R, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholagitis. Gastroenterology 1989; 96: 790–4
   PubMed Web of Science ®Google Scholar
• Sherlock S. Pathogenesis of sclerosing cholangitis: the role of nonimmune factors. Semin Liver Dis 1991; 11: 5–10
   PubMedGoogle Scholar
• Morecki R, Glaser J H, Cho S, Balistreri W F, Horwitz M S. Biliary atresia and reovirus type 3 infection. N Engl J Med 1982; 307: 481–4
   PubMed Web of Science ®Google Scholar
• Minuk G Y, Rascanin N, Paul R W, Lee P WK, Buchan K, Kelly J K. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1987; 5: 8–13
   PubMed Web of Science ®Google Scholar
• Finegold M J, Carpenter R J. Obliterative cholangitis due to cytomegalovirus: a possible precursor of paucity of intrahepatic bile ducts. Hum Pathol 1982; 13: 662–5
   PubMedGoogle Scholar
• O'Grady J G, Alexander G JM, Sutherland S, Donaldson P T, Harvey F, Portmann B, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bileduct syndrome after liver transplantation. Lancet 1988; 2: 302–5
   PubMedGoogle Scholar
• Cello J P. Acquired immunodeficiency syndrome cholangi-opathy: spectrum of disease. Am J Med 1989; 86: 539–46
   PubMed Web of Science ®Google Scholar
• Mehal W Z, Hattersley A T, Chapman R W, Fleming K A. A survey of cytomegalovirus (CMV) DNA in primary sclerosing cholangitis (PSC) liver tissues using a sensitive polymerase chain reaction (PCR) based assav. J Hepatol 1992; 15: 396–9
   PubMed Web of Science ®Google Scholar
• Mason A L, Rosen G, White H, Wick M, Gelb L D, Perrillo R P. Detection of cytomegalovirus (CMV) DNA in the liver of patients with primary sclerosing cholangitis (PSC) by polymerase chain reaction. Hepatology 1991; 14: 91 A
   Google Scholar
• Dowsett J F, Miller R, Davidson R, Vaira D, Polydorou A, Cairns S R, et al. Sclerosing cholangitis in acquired immunodeficiency syndrome. Case reports and review of the literature. Scand J Gastroenterol 1988; 23: 1267–74
   PubMed Web of Science ®Google Scholar
• Pol S, Romana C, Richard S, Carnot F, Dumont J-L, Bouche H, et al. Enterocytozoon bieneusi infection in acquired immunodeficiency syndrome-related sclerosing cholangitis. Gastroenterology 1992; 102: 1778–81
   PubMed Web of Science ®Google Scholar
• Kemeny M, Battifora H, Blayney D W, Cecchi G, Goldberg A A, Leong L A, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202: 176–81
   PubMedGoogle Scholar
• Shea W J, Demas B E, Goldberg H I, Hohn D C, Ferrell L D, Kerlan R K. Sclerosing cholangitis associated with hepatic arterial FUDR chemoterapy: radiographic-histologic correlation. AJR 1986; 146: 717–21
   PubMedGoogle Scholar
• Ludwig J, Kim C H, Wiesner R H, Krom R AF. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy?. Hepatology 1989; 9: 215–8
   PubMed Web of Science ®Google Scholar
• Hohn D, Melnick J, Stagg R, Altman D, Friedman M, Ignoffo R, et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3: 98–102
   PubMed Web of Science ®Google Scholar
• Fukuzumi S, Moriya Y, Makuuchi M, Terui S. Serious chemical sclerosing cholangitis associated with hepatic arterial 5FU and MMC chemotherapy. Eur J Surg Oncol 1990; 16: 251–5
   PubMedGoogle Scholar
• Northover J MA, Terblanche J. A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 1979; 66: 379–84
   PubMedGoogle Scholar
• Terblanche J, Allison H F, Northover J MA. An ischemic basis for biliary strictures. Surgery 1983; 94: 52–7
   PubMedGoogle Scholar
• Belghiti J, Benhamou J-P, Houry S, Grenier P, Huguier M, Fékété F. Caustic sclerosing cholangitis. Arch Surg 1986; 121: 1162–5
   PubMed Web of Science ®Google Scholar
• LaRusso N F, Wiesner R H, Ludwig J, MacCarty R L, Beaver S J, Zinsmeister A R. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95: 1036–42
   PubMed Web of Science ®Google Scholar